9.49
+5.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MeiraGTx Holdings
From its filings with the US Securities and Exchange Commission
MeiraGTx Holdings is based in New York, New York. Its shares trade on Nasdaq under the ticker MGTX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $81.4m and a net loss of $114.2m. At that date it held total assets of $244.4m and shareholders' equity of −$5.8m.
We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinson’s disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manufacturing capabilities. We have two viral vector production facilities for good manufacturing practices, or GMP, internal plasmid production for GMP, as well as an in-house Quality Control hub for stability and release, all fit for Investigational New Drug application (IND) through commercial supply. In addition, we have developed a proprietary manufacturing platform with industry-leading yield and quality aspects and commercial readiness. Our core capabilities in viral vector and capsid optimization allow increased potency, decreased dose and significantly reduced cost of goods for our genetic medicines. We have developed a transformative gene regulation platform using bespoke synthetic riboswitch technology invented in-house that allows for the precise, dose-responsive expression of any transgene under the control of oral small molecules.
Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Jun 2018
- Employees
- 400
- Website
- meiragtx.com ↗
- Head office
- 655 THIRD AVENUE, NEW YORK, NY, 10017
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Keith HarrisIndependent Chairman of the Board$529,120
- Dr. Alexandria ForbesPresident, Chief Executive Officer, Director, since 2015$6.9m
- Mr. Richard GirouxChief Financial Officer, Chief Operating Officer$6.7m
- Mr. Robert WollinGeneral Counsel, Secretary
- Dr. Stuart NaylorChief Development Officer, since 2015$2.0m
- Mr. Robert ZeldinChief Medical Officer$4.0m
- Ms. Ellen HukkelhovenIndependent Director$219,150
- Mr. Lord MendozaIndependent Director$314,204
- Ms. Nicole SeligmanIndependent Director$323,918
- Mr. Thomas ShenkIndependent Director$313,904
- Dr. Debra YuIndependent Director$303,107
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 80
- Social
- 75
- Governance
- 66
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Advanced Gene Therapy Portfolio: MeiraGTx Holdings PLC possesses a strong portfolio of cutting-edge gene therapy products, providing potential solutions for various genetic disorders. This portfolio enables the company to offer innovative and effective treatment options for patients.
- Robust Research and Development: The company heavily invests in research and development activities, driving continuous innovation and ensuring a steady pipeline of novel gene therapy candidates. This commitment to R&D enables MeiraGTx to stay at the forefront of gene therapy advancements.
- Strategic Partnerships: MeiraGTx has established valuable collaborations with leading academic institutions, medical centers, and pharmaceutical companies. These partnerships facilitate access to additional expertise, resources, and financial support, enhancing the company's capabilities and potential for success.
Weaknesses
- Limited Commercial Portfolio: While MeiraGTx possesses an impressive gene therapy pipeline, it currently has a limited number of products on the market. The company's success heavily depends on obtaining regulatory approvals and successfully commercializing its candidates, which may pose risks and delays.
- Reliance on Clinical Trials: MeiraGTx's success is largely dependent on the successful outcomes of its ongoing clinical trials. Any setbacks or negative results during these trials can significantly impact the company's future prospects and investor confidence.
- Competitive Industry Landscape: The gene therapy market is highly competitive, with numerous companies vying for market share. MeiraGTx faces competition from both established pharmaceutical companies and emerging biotech firms, which may limit its market penetration and growth.
Opportunities
- Increasing Gene Therapy Demand: As the understanding of genetic disorders and the potential of gene therapy continues to grow, there is an increasing demand for effective gene therapies. MeiraGTx can leverage this trend to expand its market presence and capture a larger share of the growing gene therapy market.
- Regulatory Support: Regulatory bodies worldwide are recognizing the potential of gene therapy and streamlining processes to expedite approvals. MeiraGTx can benefit from favorable regulatory environments, enabling faster development, approval, and commercialization of its gene therapy candidates.
- Collaborations and Partnerships: The company can explore additional collaborations and partnerships to diversify its portfolio and access new therapeutic areas. Collaborations can also provide opportunities for shared research and development costs, enhancing MeiraGTx's financial capabilities.
Threats
- Regulatory and Compliance Challenges: Gene therapy is a complex field, subject to rigorous regulatory oversight. MeiraGTx must navigate through evolving regulations, potential safety concerns, and compliance issues, which can pose challenges and delays during clinical trials and commercialization.
- Intellectual Property Risks: As a leader in gene therapy, MeiraGTx faces the risk of intellectual property infringements and legal disputes with competitors. Protecting and enforcing its patents and intellectual property rights is crucial to maintaining a competitive advantage in the market.
- Market Uncertainties: The gene therapy market is still relatively new and evolving. Market dynamics, pricing pressures, and reimbursement policies pose uncertainties that can impact MeiraGTx's financial performance and market growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.